H7T2 Stock Overview
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
HUTCHMED (China) Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£2.30 |
| 52 Week High | UK£3.82 |
| 52 Week Low | UK£2.06 |
| Beta | 0.68 |
| 1 Month Change | -2.54% |
| 3 Month Change | -7.26% |
| 1 Year Change | -35.03% |
| 3 Year Change | 42.86% |
| 5 Year Change | -38.83% |
| Change since IPO | -59.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| H7T2 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.7% | -7.1% | 0.8% |
| 1Y | -35.0% | -27.3% | 15.0% |
Return vs Industry: H7T2 underperformed the German Pharmaceuticals industry which returned -27.3% over the past year.
Return vs Market: H7T2 underperformed the German Market which returned 15% over the past year.
Price Volatility
| H7T2 volatility | |
|---|---|
| H7T2 Average Weekly Movement | 15.3% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: H7T2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: H7T2's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,811 | Wei-Guo Su | www.hutch-med.com |
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML).
HUTCHMED (China) Limited Fundamentals Summary
| H7T2 fundamental statistics | |
|---|---|
| Market cap | €2.06b |
| Earnings (TTM) | €33.45m |
| Revenue (TTM) | €558.67m |
Is H7T2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| H7T2 income statement (TTM) | |
|---|---|
| Revenue | US$630.20m |
| Cost of Revenue | US$560.99m |
| Gross Profit | US$69.21m |
| Other Expenses | US$31.48m |
| Earnings | US$37.73m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.044 |
| Gross Margin | 10.98% |
| Net Profit Margin | 5.99% |
| Debt/Equity Ratio | 10.7% |
How did H7T2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 03:53 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HUTCHMED (China) Limited is covered by 48 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| John Newman | Canaccord Genuity |
| Adam McCarter | Cavendish |